Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.08.2018 | Case report

Gefitinib

Development of gefitinib resistance: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Nonagase Y, et al. Treatment of EGFR mutation-positive non-small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: A case report. Oncotarget 9: 29532-29535, No. 50, 29 Jun 2018. Available from: URL: http://doi.org/10.18632/oncotarget.25687 - Japan Nonagase Y, et al. Treatment of EGFR mutation-positive non-small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: A case report. Oncotarget 9: 29532-29535, No. 50, 29 Jun 2018. Available from: URL: http://​doi.​org/​10.​18632/​oncotarget.​25687 - Japan
Metadaten
Titel
Gefitinib
Development of gefitinib resistance: case report
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-50010-y

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Vedolizumab

Case report

Nilotinib

Case report

Allopurinol

Case report

Multiple drugs